Healthcare / Drug Manufacturers - Specialty & GenericKSE
$7800.00
-210.00 (-2.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $1.6B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$0
P/E
N/A
•EV/EBITDA
9.9x
↓ROE
2.9%
↑Gross Margin
42.7%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.2%
FCF CAGR
-5.9%
FCF margin
0.6%
FCF / Net income
0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $272.42B · net income $6.90B · FCF $1.60B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $272.42B | $272.42B | $268.68B | $266.67B | $247.77B |
| Net Income | $6.90B | $6.90B | $9.03B | $-2.41B | $19.39B |
| EBITDA | $24.63B | $24.63B | $23.65B | $13.40B | $37.75B |
| Gross Margin | 42.7% | 42.7% | 41.4% | 43.7% | 43.7% |
| Operating Margin | 1.8% | 1.8% | 3.6% | 6.1% | 5.8% |
| Net Margin | 2.5% | 2.5% | 3.4% | -0.9% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.46 | 0.32 | 0.32 |
| Current Ratio | 0.93 | 0.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.60B | $1.60B | $-35.01B | $7.79B | $1.93B |
| Returns | |||||
| ROE | 2.9% | 2.9% | 3.8% | -1.1% | 8.3% |
| Valuation | |||||
| EV/EBITDA | 9.86 | 9.86 | 12.56 | 27.50 | 11.81 |
| P/B | 0.59 | 0.59 | 0.82 | 1.32 | 1.62 |
| Growth & Yield | |||||
| Revenue Growth | 1.4% | 1.4% | 0.8% | 7.6% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.4%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-35.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.